openPR Logo
Press release

US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028

05-19-2022 05:41 PM CET | Health & Medicine

Press release from: Kuick Resarch

US Cancer Antibodies Market, Drug Sales, Patent and Clinical

US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028 Report Highlights:

* US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028
* US Cancer Antibodies Market To Witness More Than 200% Absolute Growth
* Current and Future market Projections by Drugs and Therapeutic Class
* Clinical Trials Insight On by Company, Indication, Patient Segment and Phase
* Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021
* Insight on FDA Approved 61 Cancer Antibodies Available in US Market
* Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
* US Cancer Biosimilar Market Opportunity Insight

Download Report: https://www.kuickresearch.com/report-us-cancer-antibodies-market

In last few years, therapeutic antibodies have gained maximum share in the US cancer therapeutics market. Their ability to specifically target the antigens on cancer has enabled the development of several targeted therapies. Further, advancement in the field of biotechnology has also led to development of new generation therapeutic agents. To date, several modalities of therapeutic antibodies including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, and radiolabelled antibodies have been approved by US FDA which has shown robust response in the market. These are indicated for the management of several cancers including breast cancer, lung cancer, blood cancer, colorectal cancer, and other malignancies.

In 2021, immune checkpoint inhibitors segment hold the maximum share in the US cancer antibody market owing to their unique mechanism of action. The immune checkpoint inhibitors act by blocking the checkpoint protein, which are responsible for the prevention of cancer cells from the action of immune system. To date, 8 immune checkpoint inhibitors have entered the US market which is showing increasing sales every year. Apart from this, researchers are also evaluating other immune checkpoint including LAG-3, TIGIT, and others which are mainly present in clinical development. Relatlimab developed by Bristol Myers Squibb is a potential LAG-3 inhibitor which is expected to gain approval in market in March 2022, thus further boosting the growth of this segment during the forecast period.

The promising response of antibody therapeutics in the management of several cancers has gained a lot of attention from researchers. To date, more than 1000 clinical trials are ongoing in US, which are evaluating the role of therapeutic antibodies as monotherapy or combinational therapy in the management of cancer. For instance, researchers have developed next generation trispecific antibodies and bispecific antibody conjugate which are in initial stages of clinical development. The large number of clinical and preclinical studies suggests the promising future of antibody therapeutics in various cancers.

US is currently dominating the global cancer antibody market is mainly attributed to the surge in prevalence of cancer and rising awareness among population regarding the availability of targeted therapies. In addition, presence of major pharmaceutical companies in the region and rising investments by them also propels the growth of market during the forecast period. Apart from this, FDA also grants special designations to expedite the drug development process including orphan drug designation, fast track designation, breakthrough therapy designation, and others. Furthermore, development of favorable reimbursement policies also enhances their uptake of novel antibody therapeutics in the region.

The US cancer antibody therapeutic market is highly crowded and consists of several key players including Novartis, Amgen, Pfizer, Gilead Sciences, AstraZeneca, Bristol Myers Squibb, among others. For instance in 2021, Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates. Further, AbbVie and I-Mab also announced collaboration for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

As per our report findings, the US cancer antibody market is expected to surpass US$ 85 Billion by 2028. Rise in incidence of various cancer conditions, increase in popularity of advance therapies, and surge in geriatric population are the key factors driving the growth of the market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer antibody therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366
https://www.kuickresearch.com/

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028 here

News-ID: 2629964 • Views: 112

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and